There is a high bar for invoking MAC-like conditions, and the Panel’s role in scrutinising such attempts to ensure deal certainty. My bet is that price reduction is entertained.
What is covered in the Full Insight:
Introduction and Dispute Overview
Material Adverse Change Details
Potential Legal and Negotiation Outcomes
Comparison to Historical Precedents
Market Implications and Conclusion
Boomeranged on Fri, 29 Aug 2025 09:24
Mayne Pharma (MYX AU) has released its FY25 results. They appear decent. (more detail in "Discussions" at the bottom). And nothing apparent to suggest a MAC has been triggered. Mayne's share price has gained (some) support this morning. FWIW - no Q&A was entertained on the investor webcast.